Further studies Ibuprofen should consider the implications of these regulatory modes based on instructive and/or stochastic models of stem cell fate decisions. In the present study, we demonstrated that specific lineage-affiliated TFs formed a resultant set of transcriptional regulation, i.e., 24 differentially expressed TFs that contributed significantly to the model were modulated by other TFs that were not differentially expressed. In summary, we obtained novel transcriptome data and developed a computational method for promoter modeling. Our method can be applied easily to other biological systems. Using these approaches, we identified transcriptional regulation modes that provide insights into how HSCs determine their phenotype. Future works that overcome the limitations of the present study, such as the inclusion of enhancer activities that appear to be important in hematopoiesis and the analysis of the influence of transcriptional heterogeneity at the single-cell level, which can be assayed using promising techniques, would refine our findings and advance our understanding of the kinetic and regulatory aspects of stem cell biology. Pompe disease shows a broad phenotypic spectrum that ranges from the severe infantile-onset form to more slowly progressing, later-onset forms. Infantile-onset Pompe disease patients have little or no GAA activity, present with hypotonia, cardiomegaly, and cardioDocosanol respiratory distress, and typically die by age 2 if untreated. Late-onset forms of Pompe disease typically show some detectable GAA activity, present in childhood or adulthood, and progress more slowly, with musculoskeletal and pulmonary involvement leading to progressive weakness and respiratory insufficiency. Enzyme replacement therapy currently is the only approved treatment for Pompe disease, administered as a biweekly intravenous infusion of recombinant human GAA. Treatment with rhGAA improves cardiac function, motor skills, and life span in infantile-onset patients, and leads to mild improvements in motor and respiratory function in late-onset patients.